Biomea Fusion, Inc. (BMEA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1599 Industrial Road
San Carlos, CA 94070
United States of America (the)
Phone
650 980 9099
Website
Sector
Healthcare
Industry
Biotechnology
Employees
37
First IPO Date
April 16, 2021
| Name | Title | Pay | Year Born |
| Michael J. Hitchcock | Interim Chief Executive Officer & Director | 867,935 | 1950 |
| Ramses Erdtmann | Co-Founder, President, Chief Operating Officer & Director | 636,485 | 1963 |
| Caroline Perez- Dupont | Senior Vice President of Legal | 0 | N/A |
| Heow Tan | Chief Technology & Quality Officer | 0 | 1959 |
| Stephan Morris | Chief Development Officer | 0 | N/A |
| Ravi Upasani | Executive Vice President of Intellectual Property | 0 | N/A |
| Thorsten Kirschberg | Executive Vice President of Research | 0 | 1970 |
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.